Metabolic dysfunction-associated steatotic liver disease in internal medicine: bridging fibrosis risk stratification, new drug therapy, and practical management
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in adults with type 2 diabetes or obesity, and fibrosis stage, rather than steatosis, is a key prognostic determinant. We review fibrosis risk stratification in these adults, the randomized evidence for newly approved and repurposed drugs, and a stepwise plan combining both, with attention to Saudi Arabia. We searched PubMed in November 2026 and cite forty-six sources. A global meta-analysis places the disease in about two thirds of people with type 2 diabetes. American guidance recommends the Fibrosis-4 index (FIB-4) first; one analysis of two primary care cohorts found that it under-triages people with diabetes or obesity, but evidence conflicts, and we keep FIB-4 first and regard going directly to elastography as an unproven alternative (authors' expert opinion). Resmetirom and semaglutide improved histology in phase 3 trials and received accelerated United States approval for steatohepatitis with moderate to advanced fibrosis without cirrhosis, semaglutide on a planned interim analysis; tirzepatide improved histology in a phase 2 trial; and one open-label randomized trial found more resolution of steatohepatitis after bariatric surgery than with lifestyle modification. Pioglitazone, vitamin E and sodium-glucose cotransporter 2 inhibitors have narrower evidence. A 2026 Saudi consensus, whose literature review ended in May 2024, states that resmetirom was not yet approved there. We propose a stepwise approach (authors' expert opinion): assess fibrosis risk with FIB-4 and elastography, treat weight and cardiometabolic risk in everyone, consider drug therapy for stage 2 or 3 fibrosis, and refer early when risk is high. Abbreviations: AASLD, American Association for the Study of Liver Diseases; ADA, American Diabetes Association; ELF, Enhanced Liver Fibrosis; FIB-4, Fibrosis-4 index; MASH, metabolic dysfunction-associated steatohepatitis; MetALD, metabolic dysfunction with more alcohol intake than MASLD allows; NASH, non-alcoholic steatohepatitis; SGLT-2, sodium-glucose cotransporter 2; VCTE, vibration-controlled transient elastography.
Authors
- Majed Alqahtani (ORCID: https://orcid.org/0009-0009-9833-1310)
- Salman Mashary Alharbi (ORCID: https://orcid.org/0009-0007-8254-3429)
Institutions
- King Saud University (SA)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-22
- DOI
- https://doi.org/10.5281/zenodo.24430858
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- preprint